RxDoctor Payments Data

Ronald Navone, MD

Internal Medicine · Lodi, CANPI 1225144934

Payments from drug & device makers

$13,228in general payments, 2019–2025

Across 787 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Novo Nordisk$969
  • Lilly USA, LLC$945
  • AbbVie$907
  • Boehringer Ingelheim$864
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$13,173100%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,228 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$109,808
Medicare patients
221
Services billed
1,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide199$210,089
EliquisApixaban98$105,536
Repatha SureclickEvolocumab94$96,438
OzempicSemaglutide55$68,090
JardianceEmpagliflozin41$60,545
XareltoRivaroxaban35$56,797
Praluent PenAlirocumab43$30,544
FarxigaDapagliflozin Propanediol21$22,807
GlyxambiEmpagliflozin/Linagliptin19$18,573
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$14,770
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$12,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,952
TrulicityDulaglutide11$9,940
Ezetimibe190$8,271
DayvigoLemborexant22$7,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$945$220,029210 claims
PfizerEliquis, Paxlovid$758$108,395120 claims
Boehringer IngelheimJardiance, Glyxambi$864$79,11860 claims
Novo NordiskOzempic$969$68,09055 claims
Johnson & JohnsonXarelto$664$56,79735 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,574$37,57739 claims
GSKTrelegy Ellipta$727$10,95213 claims
Eisai Inc.Dayvigo$134$7,00622 claims
AbbVieSynthroid$907$2,29226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →